To systematically rank the efficacy and tolerability of distinct pharmacological mechanisms for metabolic dysfunction-associated steatohepatitis (MASH) and characterize their benefit–risk profiles.
Key Findings:
Ensure all findings are presented without editorial interpretation.
Interpretation:
Remove the entire section.
Limitations:
Findings based on limited histological data for SGLT2 inhibitors.
Preliminary evidence from a single pivotal trial for SGLT2 inhibitors requires confirmation in adequately powered Phase 3 trials.
Conclusion:
Revise to state only what is directly supported by the source.
